TY - JOUR
T1 - Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma
T2 - Pilot study
AU - Lin, Chieh
AU - Itti, Emmanuel
AU - Luciani, Alain
AU - Zegai, Benhalima
AU - Lin, Shih Jui
AU - Kuhnowski, Frédérique
AU - Pigneur, Frédéric
AU - Gaillard, Isabelle
AU - Paone, Gaetano
AU - Meignan, Michel
AU - Haioun, Corinne
AU - Rahmouni, Alain
PY - 2011/5
Y1 - 2011/5
N2 - The aim of this pilot study was to assess post-treatment apparent diffusion coefficient (ADC) changes of diffuse large B-cell lymphoma lesions on respiratory-gated whole-body diffusion-weighted imaging (DWI), with integrated 18F-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (PET/CT) as the reference standard. Materials and Methods: A total of 15 patients underwent both whole-body DWI (b = 50, 400, 800 s/mm2) and PET/CT before initiation and after 4 cycles of chemotherapy. ADC of residual masses (lymph node and organ lesions) was assessed both visually and quantitatively, including measurement of mean ADC (ADC). Results: After chemotherapy, among 85 examined lymph node regions, residual nodes were present in 62 (73%) regions on DWI. Of these 62 regions, 26 had persistent lymph nodes with longest transverse diameter >10 mm, ie, positive based on DWI size criteria. The mean ADC of these 26 regions increased from 0.658 >10 -3 ± 0.153 mm2/s (standard deviation) at baseline to 1.501 × 10-3 ± 0.307 mm2/s (paired t test, P < 0.0001). Only 6 of these 26 regions were considered positive on PET/CT. Combining visual ADC analysis to size criteria reduced the number of false-positive results of DWI from 20 to 2 regions. For organ involvement, ADC values also increased compared with baseline (1.558 × 10-3 ± 0.424 mm2/s vs. 0.675 × 10-3 ± 0.135 mm2/s, respectively; P = 0.0009). Conclusions: Whole-body DWI with ADC mapping can show a significant increase in ADC values of residual masses persisting after treatment and may help to assess the treatment response in patients with diffuse large B-cell lymphoma.
AB - The aim of this pilot study was to assess post-treatment apparent diffusion coefficient (ADC) changes of diffuse large B-cell lymphoma lesions on respiratory-gated whole-body diffusion-weighted imaging (DWI), with integrated 18F-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (PET/CT) as the reference standard. Materials and Methods: A total of 15 patients underwent both whole-body DWI (b = 50, 400, 800 s/mm2) and PET/CT before initiation and after 4 cycles of chemotherapy. ADC of residual masses (lymph node and organ lesions) was assessed both visually and quantitatively, including measurement of mean ADC (ADC). Results: After chemotherapy, among 85 examined lymph node regions, residual nodes were present in 62 (73%) regions on DWI. Of these 62 regions, 26 had persistent lymph nodes with longest transverse diameter >10 mm, ie, positive based on DWI size criteria. The mean ADC of these 26 regions increased from 0.658 >10 -3 ± 0.153 mm2/s (standard deviation) at baseline to 1.501 × 10-3 ± 0.307 mm2/s (paired t test, P < 0.0001). Only 6 of these 26 regions were considered positive on PET/CT. Combining visual ADC analysis to size criteria reduced the number of false-positive results of DWI from 20 to 2 regions. For organ involvement, ADC values also increased compared with baseline (1.558 × 10-3 ± 0.424 mm2/s vs. 0.675 × 10-3 ± 0.135 mm2/s, respectively; P = 0.0009). Conclusions: Whole-body DWI with ADC mapping can show a significant increase in ADC values of residual masses persisting after treatment and may help to assess the treatment response in patients with diffuse large B-cell lymphoma.
KW - apparent diffusion coefficient mapping
KW - diffuse large B-cell lymphoma
KW - fluorodeoxyglucose positron emission tomography/computed tomography
KW - treatment response
KW - whole-body diffusion-weighted imaging
UR - https://www.scopus.com/pages/publications/79954829586
U2 - 10.1097/RLI.0b013e3182087b03
DO - 10.1097/RLI.0b013e3182087b03
M3 - 文章
C2 - 21263330
AN - SCOPUS:79954829586
SN - 0020-9996
VL - 46
SP - 341
EP - 349
JO - Investigative Radiology
JF - Investigative Radiology
IS - 5
ER -
